Company Overview: BioRestorative Therapies, Inc. is a regenerative medicine company focused on stem cell-based therapies, with key programs targeting disc/spine diseases and metabolic disorders.
CEO Interview: CEO Lance Alstodt discussed the company's recent clinical and regulatory achievements in an interview on "The Big Biz Show," which will be aired across various platforms globally.
BRTX
$1.11+Infinity%1D
Analyst Views on BRTX
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
Low
8.00
Averages
8.00
High
8.00
Current: 1.110
Low
8.00
Averages
8.00
High
8.00
No data
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
